002437 誉衡药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入539,106-2.20%2,135,4512,440,7322,626,0393,107,945
减:营业总成本463,883-6.01%1,906,2012,218,7952,489,2943,045,953
    其中:营业成本293,3934.17%1,167,0821,135,9121,092,7111,338,755
               财务费用774232.37%(341)(1,068)31,31246,748
               资产减值损失(405)54.00%(10,279)(4,866)(3,304)(102,397)
公允价值变动收益17,634395.43%5,978(13,979)(17,934)(24,752)
投资收益436133.45%136,5255,251(23,438)(244,815)
    其中:对联营企业和合营企业的投资收益(55)-63.38%130,790(251)(24,755)(246,426)
营业利润107,26955.31%404,911284,853175,047(270,085)
利润总额107,13055.37%409,617283,692176,778(269,679)
减:所得税费用10,46349.07%27,26041,15248,07819,839
净利润96,66756.09%382,357242,540128,701(289,518)
减:非控股权益1,7413.68%5,4529,7818,3661,811
股东净利润94,92657.55%376,905232,759120,334(291,329)

市场价值指针
每股收益 (元) *0.04358.03%0.1720.1060.055-0.133
每股派息 (元) *------------
每股净资产 (元) *1.07124.42%1.0280.8560.7560.742
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容